Drug-induced hepatic steatosis

Seminars in Liver Disease

Volumn 34, Issue 2, 2014, Pages 205-214

  Amacher, David E ^a   Chalasani, Naga ^b  

^a Sciadvisor Toxicology Consultant   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

drug induced hepatic steatosis; drug induced steatohepatitis

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; AMIODARONE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBAMAZEPINE; COCAINE; DEXAMETHASONE; DIDANOSINE; DILTIAZEM; FAT DROPLET; FATTY ACID; FIALURIDINE; FLUOROURACIL; LAMIVUDINE; LOMITAPIDE; MESALAZINE; METHOTREXATE; MIPOMERSEN; NUCLEOSIDE ANALOG; PERHEXILINE MALEATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TAMOXIFEN; TENOFOVIR; TETRACYCLINE; TRIACYLGLYCEROL; VALPROIC ACID; VERY LOW DENSITY LIPOPROTEIN; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTIRETROVIRUS AGENT; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID;

APOPTOSIS; ARTICLE; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG SAFETY; FATTY ACID OXIDATION; FATTY LIVER; HUMAN; LIPID STORAGE; LIPIDOSIS; LIVER CELL; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; LIVER MITOCHONDRION; LYSOSOME STORAGE DISEASE; METABOLISM; PATHOLOGY;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG EVALUATION, PRECLINICAL; FATTY LIVER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYSOSOMAL STORAGE DISEASES; METHOTREXATE; MITOCHONDRIA, LIVER; PHOSPHOLIPIDS; TAMOXIFEN; VALPROIC ACID;

EID: 84901746995     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1375960     Document Type: Article

References (83)

1. Hoyumpa A. M. Jr, Greene H. L., Dunn G. D., Schenker S. Fatty liver: biochemical and clinical considerations. Am J Dig Dis: 1975; 20 12 1142 1170
2. Kleiner D. E., Brunt E. M., Van Natta M., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology: 2005; 41 6 1313 1321 (Pubitemid 40770284)
3. Wieckowska A., McCullough A. J., Feldstein A. E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology: 2007; 46 2 582 589 (Pubitemid 47344794)
4. Neuschwander-Tetri B. A., Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology: 2003; 37 5 1202 1219 (Pubitemid 36538699)
5. Levene A. P., Kudo H., Thursz M. R., Anstee Q. M., Goldin R. D. Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver? Hepatology: 2010; 51 5 1859, author reply 1859-1860
6. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med: 2000; 132 2 112 117 (Pubitemid 30044177)
7. Gupte P., Amarapurkar D., Agal S., et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol: 2004; 19 8 854 858 (Pubitemid 39093200)
8. Ludwig J., Viggiano T. R., McGill D. B., Oh B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc: 1980; 55 7 434 438 (Pubitemid 10057164)
9. Brunt E. M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis: 2001; 21 1 3 16 (Pubitemid 32240482)
10. Aravinthan A., Scarpini C., Tachtatzis P., et al. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J Hepatol: 2013; 58 3 549 556
11. Sheth S. G., Gordon F. D., Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med: 1997; 126 2 137 145 (Pubitemid 27058588)
12. Gentile C. L., Pagliassotti M. J. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem: 2008; 19 9 567 576
13. Chavez-Tapia N. C., Rosso N., Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol: 2012; 12 20
14. Musso G., Gambino R., Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res: 2013; 52 1 175 191
15. Ioannou G. N., Haigh W. G., Thorning D., Savard C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J Lipid Res: 2013; 54 5 1326 1334
16. Buechler C., Weiss T. S. Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab: 2011; 12 1 24 34
17. Gómez-Lechón M. J., Jover R., Donato M. T. Cytochrome p450 and steatosis. Curr Drug Metab: 2009; 10 7 692 699
18. McKenzie R., Fried M. W., Sallie R., et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med: 1995; 333 17 1099 1105
19. Kleiner D. E., Gaffey M. J., Sallie R., et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol: 1997; 10 3 192 199 (Pubitemid 27130467)
20. Honkoop P., Scholte H. R., de Man R. A., Schalm S. W. Mitochondrial injury. Lessons from the fialuridine trial. Drug Saf: 1997; 17 1 1 7 (Pubitemid 27367719)
21. Lai Y., Tse C. M., Unadkat J. D. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem: 2004; 279 6 4490 4497 (Pubitemid 38199039)
22. Donato M. T., Martínez-Romero A., Jiménez N., et al. Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol Interact: 2009; 181 3 417 423
23. Fujimura H., Murakami N., Kurabe M., Toriumi W. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J Appl Toxicol: 2009; 29 4 356 363
24. Amacher D. E., Martin B. A. Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam Appl Toxicol: 1997; 40 2 256 263
25. Barone L. R., Boyer S., Damewood J. R. Jr, Fikes J., Ciaccio P. J. Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than nonphospholipogenic pharmaceuticals in preclinical toxicology studies. J Toxicol: 2012; 2012: Article ID 308594
26. Hanumegowda U. M., Wenke G., Regueiro-Ren A., Yordanova R., Corradi J. P., Adams S. P. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Chem Res Toxicol: 2010; 23 4 749 755
27. Reasor M. J., Hastings K. L., Ulrich R. G. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf: 2006; 5 4 567 583 (Pubitemid 44468453)
28. Kodavanti U. P., Mehendale H. M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev: 1990; 42 4 327 354
29. Muehlbacher M., Tripal P., Roas F., Kornhuber J. Identification of drugs inducing phospholipidosis by novel in vitro data. ChemMedChem: 2012; 7 11 1925 1934
30. Choi S. S., Kim J. S., Valerio L. G. Jr, Sadrieh N. In silico modeling to predict drug-induced phospholipidosis. Toxicol Appl Pharmacol: 2013; 269 2 195 204
31. Rao M. S., Reddy J. K. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis: 2001; 21 1 43 55
32. Okumura T. Role of lipid droplet proteins in liver steatosis. J Physiol Biochem: 2011; 67 4 629 636
33. Straub B. K., Stoeffel P., Heid H., Zimbelmann R., Schirmacher P. Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology: 2008; 47 6 1936 1946 (Pubitemid 351945561)
34. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol: 2008; 22 4 335 353
35. Kawano Y., Nishiumi S., Tanaka S., et al. Activation of the aryl hydrocarbon receptor induces hepatic steatosis via the upregulation of fatty acid transport. Arch Biochem Biophys: 2010; 504 2 221 227
36. Browning J. D., Horton J. D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest: 2004; 114 2 147 152 (Pubitemid 39071617)
37. Begriche K., Massart J., Robin M. A., Borgne-Sanchez A., Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol: 2011; 54 4 773 794
38. Adams L. A., Angulo P., Lindor K. D. Nonalcoholic fatty liver disease. CMAJ: 2005; 172 7 899 905 (Pubitemid 40543601)
39. Ishak K. G., Zimmerman H. J., Ray M. B. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alcohol Clin Exp Res: 1991; 15 1 45 66
40. Jaeschke H., Gores G. J., Cederbaum A. I., Hinson J. A., Pessayre D., Lemasters J. J. Mechanisms of hepatotoxicity. Toxicol Sci: 2002; 65 2 166 176 (Pubitemid 34121108)
41. Jolly R. A., Ciurlionis R., Morfitt D., et al. Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression. Toxicol Pathol: 2004; 32 02 19 25 (Pubitemid 38993912)
42. Grieco A., Forgione A., Miele L., et al. Fatty liver and drugs. Eur Rev Med Pharmacol Sci: 2005; 9 5 261 263 (Pubitemid 41387388)
43. Mattar W., Juliar B., Gradus-Pizlo I., Kwo P. Y. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. J Gastrointestin Liver Dis: 2009; 18 4 419 423
44. Kneeman J. M., Misdraji J., Corey K. E. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol: 2012; 5 3 199 207
45. Jordan V. C. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov: 2003; 2 3 205 213 (Pubitemid 37361665)
46. Saphner T., Triest-Robertson S., Li H., Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer: 2009; 115 14 3189 3195
47. Nguyen M. C., Stewart R. B., Banerji M. A., Gordon D. H., Kral J. G. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord: 2001; 25 2 296 298
48. Bruno S., Maisonneuve P., Castellana P., et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ: 2005; 330 7497 932
49. Larosche I., Lettéron P., Fromenty B., et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther: 2007; 321 2 526 535 (Pubitemid 46624526)
50. Lelliott C. J., López M., Curtis R. K., et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J: 2005; 19 9 1108 1119 (Pubitemid 40946436)
51. Ohnishi T., Ogawa Y., Saibara T., et al. CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Hepatol Res: 2005; 33 2 178 180 (Pubitemid 41799800)
52. Lindsay K., Gough A. Psoriatic arthritis, methotrexate and the liver-are rheumatologists putting their patients at risk? Rheumatology (Oxford): 2008; 47 7 939 941 (Pubitemid 351865911)
53. Langman G., Hall P. M., Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol: 2001; 16 12 1395 1401 (Pubitemid 34107409)
54. Aithal G. P., Haugk B., Das S., Card T., Burt A. D., Record C. O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther: 2004; 19 4 391 399 (Pubitemid 38297107)
55. Luef G. J., Waldmann M., Sturm W., et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol: 2004; 55 5 729 732 (Pubitemid 38544334)
56. Luef G., Rauchenzauner M., Waldmann M., et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res: 2009; 86 1 42 47
57. Zaccara G., Messori A., Moroni F. Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet: 1988; 15 6 367 389
58. Knapp A. C., Todesco L., Beier K., et al. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. J Pharmacol Exp Ther: 2008; 324 2 568 575 (Pubitemid 351185875)
59. Aires C. C., Ijlst L., Stet F., et al. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol: 2010; 79 5 792 799
60. Cuchel M., Bloedon L. T., Szapary P. O., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med: 2007; 356 2 148 156 (Pubitemid 46089675)
61. Bell D. A., Hooper A. J., Watts G. F., Burnett J. R. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc Health Risk Manag: 2012; 8 651 659
62. Gelsinger C., Steinhagen-Thiessen E., Kassner U. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs: 2012; 72 11 1445 1455
63. McGowan M. P., Tardif J. C., Ceska R., et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE: 2012; 7 11 e49006
64. Visser M. E., Wagener G., Baker B. F., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J: 2012; 33 9 1142 1149
65. Sahebkar A., Watts G. F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther: 2013; 35 8 1082 1098
66. Cuchel M., Meagher E. A., du Toit Theron H., et al. Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet: 2013; 381 9860 40 46
67. Montessori V., Press N., Harris M., Akagi L., Montaner J. S. Adverse effects of antiretroviral therapy for HIV infection. CMAJ: 2004; 170 2 229 238 (Pubitemid 38134804)
68. Sulkowski M. S., Mehta S. H., Torbenson M., et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS: 2005; 19 6 585 592 (Pubitemid 40543981)
69. Chariot P., Drogou I., de Lacroix-Szmania I., et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol: 1999; 30 1 156 160 (Pubitemid 29023665)
70. Banerjee A., Abdelmegeed M. A., Jang S., Song B. J. Zidovudine (AZT) and hepatic lipid accumulation: implication of inflammation, oxidative and endoplasmic reticulum stress mediators. PLoS ONE: 2013; 8 10 e76850
71. Cindoruk M., Karakan T., Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol: 2007; 41 5 513 517 (Pubitemid 46642541)
72. Bani-Sadr F., Carrat F., Bedossa P., et al. ANRS HC02 - Ribavic Study team. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS: 2006; 20 4 525 531 (Pubitemid 43731596)
73. Borghi V., Bisi L., Manzini L., Cossarizza A., Mussini C. Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. Infection: 2013; 41 2 425 429
74. Martinez V., Ta T. D., Mokhtari Z., et al. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. BMC Res Notes: 2012; 5 180
75. Miyake K., Hayakawa K., Nishino M., Morimoto T., Mukaihara S. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol: 2005; 12 6 722 727 (Pubitemid 40791088)
76. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol: 2006; 24 31 4983 4990 (Pubitemid 46631400)
77. Wolf P. S., Park J. O., Bao F., et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg: 2013; 216 1 41 49
78. Pilgrim C. H., Satgunaseelan L., Pham A., et al. Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity. HPB (Oxford): 2012; 14 5 333 340
79. Raman M., Allard J. Non alcoholic fatty liver disease: a clinical approach and review. Can J Gastroenterol: 2006; 20 5 345 349
80. Anthérieu S., Rogue A., Fromenty B., Guillouzo A., Robin M. A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology: 2011; 53 6 1895 1905
81. Khan A. Z., Morris-Stiff G., Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg: 2009; 16 2 137 144
82. Maor Y., Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol: 2013;: 2013;: Article ID 815105
83. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol: 2009; 62 6 481 492